AI-generated summary
This review gathers published literature on photobiomodulation as a possible approach to prevent or treat Alzheimer's disease, aiming to translate laboratory findings into a concise suggested treatment protocol. The authors report promising results in cell culture and animal studies, and describe first human case studies as providing reasons for larger clinical trials. The abstract itself does not report the number of studies reviewed or any patient outcomes.
- Who or what was studied
- Patients with Alzheimer's disease or at risk of it, and cell culture and animal models, as covered by the review; the abstract does not specify numbers.
- Limits stated in the abstract
- The abstract is a narrative review, does not state how many studies were included or their quality, and reports mainly cell and animal findings with only first human case studies.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on journals.sagepub.com.
Record from PubMed, a service of the National Library of Medicine.
How to read a review: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Dementia, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.